Reaction

Soft Tissue Infection reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,789 reports · 95 co-occurring drugs

As of the last recalculation, Soft Tissue Infection appears in 1,789 FAERS reports alongside 95 co-occurring drug terms. The strongest observed disproportionality signal is AZACITIDINE FOR (PRR 33.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Azacitidine For	51	33.5	33.6
Posaconazole Delayed-Release	24	25.8	25.8
Azacitidine	61	24.7	24.8
Posaconazole	30	21.8	21.9
Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride And Dextrose	15	21.5	21.5
Thiotepa	16	19.7	19.7
Daptomycin	15	19.1	19.1
Dronabinol	13	18.9	19.0
Ado-Trastuzumab Emtansine	13	18.1	18.1
Amphotericin B	19	17.8	17.8
Erythropoietin	28	16.1	16.1
Cytarabine	78	15.7	15.8
Pegaspargase	16	15.3	15.4
Busulfan	20	14.9	15.0
Fludarabine Phosphate	44	13.3	13.3
Piperacillin Sodium And Tazobactam Sodium	22	13.2	13.2
Piperacillin And Tazobactam	14	12.8	12.8
Mercaptopurine	18	12.2	12.2
Sirolimus	14	12.2	12.2
Sofosbuvir	20	11.9	11.9
Melphalan	23	11.9	11.9
Venetoclax	61	11.9	11.9
Cefazolin	9	11.5	11.5
Fosaprepitant Dimeglumine	13	11.1	11.1
Filgrastim	35	11.0	11.0
Pertuzumab	25	10.8	10.8
Melphalan Hydrochloride	23	10.8	10.8
Mycophenolate Mofetil	118	10.8	10.8
Mycophenolate Mofetil Hydrochloride	118	10.7	10.7
Piperacillin Sodium,Tazobactam Sodium	24	10.7	10.7
Bendamustine Hcl	14	10.6	10.6
Fam-Trastuzumab Deruxtecan-Nxki	9	10.4	10.4
Amikacin	15	10.3	10.3
Obinutuzumab	14	10.0	10.0
Everolimus Tablets	14	9.8	9.8
Cefazolin Sodium	10	9.7	9.7
Cyclophosphamide Injection, Solution	132	9.3	9.3
Cyclophosphamide	132	9.3	9.3
Cyclophosphamide For Injection	132	9.3	9.3
Diclofenac	66	9.2	9.2
Voriconazole Injection	17	9.2	9.2
Loperamide Hydrochloride Oral	8	9.2	9.2
Ganciclovir	8	9.1	9.1
Tacrolimus Ointment 0.1%	93	9.1	9.1
Tacrolimus Extended-Release Capsules	93	9.1	9.1
Adalimumab-Fkjp	35	8.9	9.0
Ganciclovir Sodium	8	8.8	8.8
Exemestane	16	8.8	8.8
Adalimumab-Aaty	35	8.8	8.8
Atovaquone	6	8.7	8.7
Doxorubicin Hydrochloride	24	8.7	8.7
Mycophenilic Acid	15	8.5	8.5
Doxorubicin	62	8.3	8.4
Thalidomide	26	8.3	8.4
Adalimumab-Adaz	36	8.1	8.1
Vincristine Sulfate	20	8.0	8.0
Carfilzomib	19	7.9	7.9
Granisetron Hydrochloride	7	7.8	7.8
Hydroxyurea	14	7.8	7.8
Aprepitant	12	7.6	7.6
Linezolid	19	7.5	7.5
Tacrolimus	96	7.5	7.5
Leucovorin Calcium	12	7.3	7.4
Voriconazole	19	7.3	7.3
Loperamide Hcl	8	7.3	7.3
Baricitinib	6	7.3	7.3
Meropenem	19	7.0	7.0
Micafungin Sodium	5	6.9	6.9
Brentuximab Vedotin	6	6.8	6.8
Trastuzumab	39	6.7	6.7
Blinatumomab	6	6.7	6.7
Granisetron	6	6.7	6.7
Paricalcitol	8	6.6	6.6
Nevirapine	5	6.5	6.5
Docetaxel Anhydrous	36	6.3	6.3
Docetaxel	36	6.3	6.3
Gemcitabine	21	6.3	6.3
Everolimus	27	6.3	6.3
Cladribine	5	6.1	6.1
Ifosfamide	11	6.0	6.0
Cetuximab	16	6.0	6.0
Etoposide	37	6.0	6.0
Bortezomib	41	5.4	5.4
Tofacitinib Citrate	6	5.3	5.3
Gemcitabine Hydrochloride	24	5.3	5.3
Atezolizumab	17	5.1	5.1
Capecitabine	39	5.0	5.0
Erlotinib	4	4.8	4.8
Ribavirin	24	4.4	4.4
Daratumumab	14	4.1	4.1
Lenvatinib	11	3.9	3.9
Vemurafenib	4	3.9	3.9
Crizotinib	4	3.7	3.7
Ipilimumab	13	3.5	3.5
Glecaprevir And Pibrentasvir	3	3.2	3.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.